Denosumab: an Emerging Therapy in Pediatric Bone Disorders
1Section on Skeletal Disorders and Mineral Homeostasis, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Building 30 Room 228 MSC 4320, Bethesda, MD, 20982, USA. boyceam@mail.nih.gov.
Current Osteoporosis Reports
|June 24, 2017
Summary
Denosumab shows promise for pediatric skeletal disorders by reducing bone turnover and increasing bone density. However, rapid reversibility can cause severe hypercalcemia, requiring further research for safe use in children.
Area of Science:
- Pediatric endocrinology
- Bone biology
- Pharmacology
Background:
- Denosumab (RANKL inhibitor) is established for adult bone disorders.
- Pediatric data on denosumab is limited but emerging.
- Understanding denosumab's role in pediatric skeletal health is crucial.
Purpose of the Study:
- To review the current use of denosumab in children.
- To evaluate the efficacy and safety of denosumab in pediatric skeletal disorders.
- To highlight the unique properties and risks of denosumab in pediatric populations.
Main Methods:
- Review of existing pediatric clinical data and case reports.
- Analysis of denosumab's mechanism of action on bone turnover.
- Comparison of denosumab's effects with bisphosphonates in pediatric contexts.
Main Results:
- Denosumab may decrease bone turnover and increase bone density in children.
- Evidence suggests potential benefits in certain pediatric skeletal neoplasms.
- Rapid reversibility of denosumab's effect can lead to rebound hypercalcemia.
Conclusions:
- Denosumab is a promising therapeutic option for pediatric skeletal disorders.
- Safety concerns regarding mineral homeostasis and rebound hypercalcemia need careful management.
- Further research is essential to optimize denosumab's use and mitigate risks in children.
Related Concept Videos
01:40Bone Remodeling
40.7K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.7K
01:29Bone Disorders
5.7K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.7K
01:31Osteoclasts in Bone Remodeling
4.4K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.4K
01:55Bone Structure
52.2K
Within the skeletal system, the structure of a bone, or osseous tissue, can be exemplified in a long bone, like the femur, where there are two types of osseous tissue: cortical and cancellous.
52.2K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
384
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
384
01:24Bone Formation by Endochondral Ossification
10.2K
Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
10.2K